Journal
GENETIC TESTING AND MOLECULAR BIOMARKERS
Volume 23, Issue 4, Pages 264-269Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/gtmb.2018.0173
Keywords
circulating tumor DNA; liquid biopsy; target region sequencing; renal cell carcinoma; breast cancer
Ask authors/readers for more resources
Background: Qualitative and quantitative detection of circulating tumor DNA (ctDNA) is a liquid biopsy technology used for early cancer diagnosis. However, the plasma ctDNA content is extremely low, so it is difficult to detect somatic mutations of tumors using conventional sequencing methods. Target region sequencing (TRS) technology, through enrichment of the target genomic region followed by next generation sequencing, overcomes this challenge and has been widely used in ctDNA sequencing. Methods: We designed a ctDNA sequencing panel to capture 128 tumor genes, and tested the performance of the panel by running TRS for ctDNA of a clear cell renal cell carcinoma (ccRCC) patient and 12 breast cancer patients. Results: TRS using the new ctDNA panel at more than 500 x coverage depth achieved almost the same accuracy as traditional whole-exome sequencing (WES). PBRM1 p.L641V was detected in the plasma sample of the ccRCC patient with an allele frequency of 0.2%. The ctDNA of 12 breast cancer patients was sequenced at a depth of 500-fold, achieving 99.89% coverage; 34 genes were detected with mutations, including the drug target genes BRCA2, PTEN, TP53, APC, KDR, and NOTCH2. Conclusions: This TRS new ctDNA panel can be used to detect mutations in cell-free DNA from multiple types of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available